Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma

Individuals with hematologic malignancies are at increased risk for severe coronavirus disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity are scarce. Here we present an observational study with expanded methodological analysis of a longitudinal, primarily BNT162b2 mR...

Descripción completa

Detalles Bibliográficos
Autores principales: Keppler-Hafkemeyer, Andrea, Greil, Christine, Wratil, Paul R., Shoumariyeh, Khalid, Stern, Marcel, Hafkemeyer, Annika, Ashok, Driti, Hollaus, Alexandra, Lupoli, Gaia, Priller, Alina, Bischof, Marie L., Ihorst, Gabriele, Engelhardt, Monika, Marks, Reinhard, Finke, Jürgen, Bertrand, Hannah, Dächert, Christopher, Muenchhoff, Maximilian, Badell, Irina, Emmerich, Florian, Halder, Hridi, Spaeth, Patricia M., Knolle, Percy A., Protzer, Ulrike, von Bergwelt-Baildon, Michael, Duyster, Justus, Hartmann, Tanja N., Moosmann, Andreas, Keppler, Oliver T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886553/
https://www.ncbi.nlm.nih.gov/pubmed/36543907
http://dx.doi.org/10.1038/s43018-022-00502-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886553/
https://www.ncbi.nlm.nih.gov/pubmed/36543907
http://dx.doi.org/10.1038/s43018-022-00502-x

Ejemplares similares